Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34472299 | 0.84 | RAB9A (0.61) | ALDH1A1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL4697948 | 0.84 | DRD2 (0.51) | ALDH1A1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL20952542 | 0.83 | SMN1; SMN2 (0.56) | ALDH1A1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL34473907 | 0.83 | MAPT (0.57) | ALDH1A1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL3507910 | 0.82 | TDP1 (0.51) | ALDH1A1SMN1; SMN2POLBKMT2AEPHX2 | |
| SCHEMBL22405638 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL3427781 | 0.81 | MAPT (0.72) | ALDH1A1MAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL29067089 | 0.80 | EPHX2 (0.68) | ALDH1A1LMNASMN1; SMN2HTTPOLB | |
| SCHEMBL4029063 | 0.80 | MAPT (0.70) | ALDH1A1MAPTLMNASMN1; SMN2POLB | |
| SCHEMBL6212316 | 0.80 | MGLL (0.65) | ALDH1A1LMNASMN1; SMN2HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | ALDH1A1 3643/4885MAPT 3766/4885TP53 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.